Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BIMI International Medical, Inc. (BIMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3183+0.0073 (+2.35%)
At close: 04:00PM EDT
0.3400 +0.02 (+6.82%)
After hours: 07:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3110
Open0.3017
Bid0.3100 x 1100
Ask0.3200 x 1800
Day's Range0.3000 - 0.3330
52 Week Range0.2900 - 13.3500
Volume211,673
Avg. Volume1,912,255
Market Cap11.827M
Beta (5Y Monthly)-0.18
PE Ratio (TTM)N/A
EPS (TTM)-4.8780
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BIMI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BIMI International Medical Inc.
    DOV: Lowering target price to $138.00DOVER CORP has an Investment Rating of BUY; a target price of $138.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    BIMI Announces Second Quarter 2022 Financial Results

    NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced its financial results for the six months ended June 30, 2022. Revenues for the six months ended June 30, 2022 and 2021 were $9,947,109 and $11,424,991, respectively. Compared with the same period in 2021, revenue decreased by $1,477,882, mainly due to the decrease in pharmaceutical sales of $3,615,357. Cost of revenues

  • GlobeNewswire

    BIMI Announces Results of 2022 Annual General Meeting of Stockholders

    New York, July 15, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on July 13, 2022 at 11:00 a.m. (Beijing Time), at the offices of the Company, 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. R. China. At the Annual Meeting, BIMI: 1. Elected seven n

  • GlobeNewswire

    BIMI Enters into Definitive Agreement to Acquire Phenix Bio Inc.

    Transaction expected to expand business and fuel growth New York, July 07, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced that on July 5, 2022, the Company entered into a definitive stock purchase agreement (the "SPA") to acquire Phenix Bio Inc. (“Phenix”), a California based corporation that will distribute healthcare products. This acquisition is a critical initiative to advance the

Advertisement
Advertisement